Mopac Biologics, Inc.

Developer of oral, locally active, IL-23R antagonist for Inflammatory Bowel Disease

Founded in 2020 by a team of scientists led by Stephanie Berger based on research conducted at the Institute for Protein Design. The pre-clinical drug development company seeks to address Inflammatory Bowel Disease through de novo designed IL-23 receptor antagonists that are specifically designed to inhibit the IL-23/Th17 pathway which has been implicated in the pathogenesis of many chronic inflammatory disorders including IBD.